Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary) ; Secukinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms BE RADIANT
  • Sponsors UCB Biopharma; UCB Pharma Inc

    • Most Recent Events

    • 07 Mar 2025 According to UCB media release, pooled data form this trial will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, U.S., March 7-11.
    • 15 Jun 2024 Results assessing impact of Bimekizumab on cardiovascular inflammation-associated markers over 16 weeks from BE RADIANT trial and over 48 weeks from BE RADIANT trial presented at the 25th Annual Congress of the European League Against Rheumatism
    • 15 Nov 2023 Results comparing the efficacy of bimekizumab (BKZ) vs secukinumab (SEC) through 48 weeks (wks) for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis who had moderate to severe nail involvement at baseline, presented at the ACR Convergence 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top